Abstract
Adding anti-PD1 antibodies to 5-FU/platinum chemotherapy improves survival in a subset of advanced gastroesophageal adenocarcinoma (GEA) patients. Beyond PD-L1 expression and mismatch repair status we have limited insight into molecular predictors of response or the relative contribution of PD-1 blockade. We conducted an investigator sponsored phase II trial (n = 47) sequentially adding pembrolizumab to standard 5-FU/platinum in previously untreated advanced GEA (ClinicalTrials.gov: NCT04249739). With an overall response rate of 67% the activity paralleled phase III chemoimmunotherapy trials. To understand on-treatment tumor and immune adaptations patients underwent serial biopsy of the primary tumor, including baseline, after one cycle of 5-FU/platinum, and after the addition of pembrolizumab. We leveraged transcriptional profiling from 358,067 cells to identify multicellular networks of malignant, stromal, and immune cells after chemotherapy and concurrent chemoimmunotherapy. The relative usage of pro-tumor and anti-tumor interaction hubs differed between fast and slow progressing patients. Chemotherapy induced early on-treatment formation of hubs centered on tumor-reactive T-cell and M1-oriented macrophage interactions with pro-inflammatory cytokines in slow progressors. Faster progression was characterized by increased MUC5A and MSLN containing programs in tumor cells and M2-oriented macrophages with immunosuppressive stromal interactions. After adding pembrolizumab we observed increased CD8 T-cell infiltration by scRNAseq and multiplex immunofluorescence and development of an immunity hub involving co-variation of the tumor-reactive CXCL13 program and epithelial interferon-stimulated gene programs enriched in slow progressors. Together this data provides prospective evidence of differential early on-treatment evolution of the gastric immune microenvironment and nominates candidate cellular interactions for clinical targeting.
Competing Interest Statement
AM has served a consultant/advisory role for Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, Flare Therapeutics, venBio Partners, BioNTech, Rheos Medicines and Checkmate Pharmaceuticals, is currently a part-time Entrepreneur in Residence at Third Rock Ventures, is an equity holder in Asher Biotherapeutics and Abata Therapeutics, and has received research funding support from Bristol-Myers Squibb. YJH is employed by and holds equity in Neocella, Inc. RC is employed by and holds equity in Merck & Co. WYP is employed by and holds equity in Geninus Inc. SJK has served a consultant/advisory role for Bristol Myers Squibb, Merck, Eli Lilly, Astellas, Daiichi-Sankyo, Pieris, Natera, Novartis, AstraZeneca, Mersana, Sanofi-Aventis, Servier, and Coherus. SJK reports stock/equity in Turning Point Therapeutics. JL has served a consultant/advisory role for Mirati, Oncxerna, Seattle Genetics, Guardant AMEA, Daiichi-Sankyo, and AstraZeneca. The remaining authors have no conflicts to disclose.
Clinical Trial
NCT04249739
Funding Statement
Dana Farber Cancer Institute / Harvard CancerCare GI SPORE Career Enhancement Award (AM), Sky Foundation Pancreatic Cancer Research Grant (AM), Doris Duke Charitable Foundation Physician Scientist Fellowship (AM), the DeGregorio Family Foundation (SJK), SU2C Gastric Cancer Interception Research Team Grant (Grant Number: SU2C-AACR-DT-30-20) Award (HL, SJK, JL). This research grant is administered by the American Association for Cancer Research, the Scientific Partner of SU2C. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR20C0025 [SK]). This paper was supported by SKKU Excellence in Research Award Research Fund, Sungkyungkwan University, 2022 (JL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial protocol was approved by the Institutional Review Board (IRB) of Samsung Medical Center (Seoul, Korea; IRB No. 2019-11-089) and was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice. All patients provided written informed consent before enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Sequencing data from the patient cohort will be deposited in the European Nucleotide Archive (ENA) and will be made available at the time of publication.
